EZH 2 Palmitoylation Mediated by ZDHHC 5 in p 53-Mutant Glioma Drives Malignant Development and Progression

Gliomas with mutant p53 occurring in 30% of glioma patients exhibit therapeutic resistance and poor outcomes. In this study, we identify a novel mechanism through which mutant p53 drives cancer cell survival and malignant growth. We documented overexpression of the zinc finger protein ZDHHC5 in glioma compared with normal brain tissue and that this event tightly correlated with p53 mutations. Mechanistic investigations revealed that mutant p53 transcriptionally upregulated ZDHHC5 along with the nuclear transcription factor NF-Y. These events contributed to the development of glioma by promoting the self-renewal capacity and tumorigenicity of glioma stem-like cells, by altering the palmitoylation and phosphorylation status of the tumor suppressor EZH2. Taken together, our work highlighted ZDHHC5 as a candidate therapeutic target for management of p53-mutated gliomas. Cancer Res; 77(18); 4998–5010. 2017 AACR.

[1]  N. Butowski,et al.  The Effect of Molecular Diagnostics on the Treatment of Glioma , 2017, Current Oncology Reports.

[2]  Jian Guan,et al.  New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M , 2017, Current Neurology and Neuroscience Reports.

[3]  B. Porse,et al.  EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas , 2017, Nature Medicine.

[4]  C. Marosi,et al.  Milestones of the last 10 years , 2017, memo - Magazine of European Medical Oncology.

[5]  T. Kondo,et al.  Molecular mechanisms involved in gliomagenesis , 2017, Brain Tumor Pathology.

[6]  H. Mehdorn,et al.  Stem cell markers in glioma progression and recurrence. , 2016, International journal of oncology.

[7]  A. Arbab,et al.  p53 Mutation: Critical Mediator of Therapy Resistance against Tumor Microenvironment. , 2016, Biochemistry & physiology.

[8]  A. Hao,et al.  Melatonin inhibits tumorigenicity of glioblastoma stem‐like cells via the AKT–EZH2–STAT3 signaling axis , 2016, Journal of pineal research.

[9]  B. Garcia,et al.  Inhibition of DHHC20-Mediated EGFR Palmitoylation Creates a Dependence on EGFR Signaling. , 2016, Molecular cell.

[10]  T. Kameyama,et al.  ETV6‐LPXN fusion transcript generated by t(11;12)(q12.1;p13) in a patient with relapsing acute myeloid leukemia with NUP98‐HOXA9 , 2016, Genes, chromosomes & cancer.

[11]  Jian Hu,et al.  Glioma Stem Cells: Signaling, Microenvironment, and Therapy , 2016, Stem cells international.

[12]  T. Ferguson,et al.  Palmitoylation controls DLK localization, interactions and activity to ensure effective axonal injury signaling , 2015, Proceedings of the National Academy of Sciences.

[13]  E. Conibear,et al.  ABHD17 proteins are novel protein depalmitoylases that regulate N-Ras palmitate turnover and subcellular localization , 2015, eLife.

[14]  Yong-jie Lu,et al.  Protein S-palmitoylation and cancer. , 2015, Biochimica et biophysica acta.

[15]  L. S. Queiroz,et al.  EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation. , 2015, Arquivos de neuro-psiquiatria.

[16]  J. Rich,et al.  Cancer stem cells in glioblastoma , 2015, Genes & development.

[17]  P. Zhao,et al.  Aberrant LRP16 protein expression in primary neuroendocrine lung tumors. , 2015, International journal of clinical and experimental pathology.

[18]  M. Barbacid,et al.  H-Ras Distribution and Signaling in Plasma Membrane Microdomains Are Regulated by Acylation and Deacylation Events , 2015, Molecular and Cellular Biology.

[19]  K. Bhat,et al.  EZH2 Protects Glioma Stem Cells from Radiation-Induced Cell Death in a MELK/FOXM1-Dependent Manner , 2015, Stem cell reports.

[20]  B. Kristensen,et al.  Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma. , 2015, Advances in experimental medicine and biology.

[21]  J. Greaves,et al.  New links between S‐acylation and cancer , 2014, The Journal of pathology.

[22]  Ichiro,et al.  EZH 2 Protects Glioma Stem Cells from Radiation-Induced Cell Death in a MELK / FOXM 1-Dependent Manner , 2014 .

[23]  Yanhui Liu,et al.  Gain of Function of Mutant TP53 in Glioblastoma: Prognosis and Response to Temozolomide , 2014, Annals of Surgical Oncology.

[24]  C. Hawkins,et al.  Loss of p53 cooperates with K‐ras activation to induce glioma formation in a region‐independent manner , 2013, Glia.

[25]  D. Nam,et al.  Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. , 2013, Cancer cell.

[26]  M. Linder,et al.  Mechanism and function of DHHC S‐Acyltransferases , 2013, Biochemical Society transactions.

[27]  A. Viale,et al.  Susceptibility Loci Associated with Specific and Shared Subtypes of Lymphoid Malignancies , 2013, PLoS genetics.

[28]  Yanhui Liu,et al.  Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O6-methylguanine DNA-methyltransferase , 2013, Neurological Sciences.

[29]  Yinji Liang,et al.  R280T mutation of p53 gene promotes proliferation of human glioma cells through GSK-3β/PTEN pathway , 2012, Neuroscience Letters.

[30]  R. Huganir,et al.  Palmitoylation by DHHC5/8 Targets GRIP1 to Dendritic Endosomes to Regulate AMPA-R Trafficking , 2012, Neuron.

[31]  A. Sikorski,et al.  Human DHHC proteins: a spotlight on the hidden player of palmitoylation. , 2012, European journal of cell biology.

[32]  Benjamin F. Cravatt,et al.  DHHC5 Protein Palmitoylates Flotillin-2 and Is Rapidly Degraded on Induction of Neuronal Differentiation in Cultured Cells* , 2011, The Journal of Biological Chemistry.

[33]  Shiyun Ling,et al.  TopBP1 Mediates Mutant p53 Gain of Function through NF-Y and p63/p73 , 2011, Molecular and Cellular Biology.

[34]  M. Fukata,et al.  Protein palmitoylation in neuronal development and synaptic plasticity , 2010, Nature Reviews Neuroscience.

[35]  Arturo Alvarez-Buylla,et al.  Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. , 2009, Cancer cell.

[36]  Gerald C. Chu,et al.  P53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation , 2008, Nature.

[37]  D. Schiff,et al.  PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. , 2008, Cancer research.

[38]  Giulia Piaggio,et al.  Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. , 2006, Cancer cell.

[39]  R. Deschenes,et al.  Thematic review series: Lipid Posttranslational Modifications. Protein palmitoylation by a family of DHHC protein S-acyltransferases Published, JLR Papers in Press, April 1, 2006. , 2006, Journal of Lipid Research.

[40]  M. Hung,et al.  Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3 , 2005, Science.